摘要
作为肺癌驱动基因之一的突变表皮生长因子受体(EGFR)的发现开启了非小细胞肺癌(NSCLC)靶向治疗之门。继EGFR后发现了更多肺癌相关驱动基因,并可成为NSCLC新的治疗靶点(如ALK,ROS1,RET,KRAS,HER2,BRAF,PIK3CA,MEKI/2,MET等)。本文对新发现靶点及针对这些靶点的药物治疗进展进行综述。
Identification of EGFR mutation, one of the driver genes in lung cancer, wes so important to open the door of targeted therapy for NSCLC. More driver genes related to lung cancer had been identified and become the new targets of NSCLC, e.g. ALK, ROS1, RET, KRAS, HER2, BRAF, PIK3CA, MEK1/2, MET and so on. In this paper, we comprehensively reviewed those new targets and therapeutic advance based on targeted drivers genes.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2012年第17期2019-2024,共6页
Chinese Journal of New Drugs
关键词
非小细胞肺癌
表皮生长因子受体
驱动基因
靶点
治疗进展
non-small cell lung cancer
epidermal growth factor receptor
driver gene
target
advances in therapy
